                                                                   Pharmacological Research 157 (2020) 104859


                                                                     Contents lists available at ScienceDirect


                                                                  Pharmacological Research
                                                        journal homepage: www.elsevier.com/locate/yphrs


Review

Candidate drugs against SARS-CoV-2 and COVID-19                                                                                                                        T
                             a                                b                          b                         c                            d,
Dwight L. McKee , Ariane Sternberg , Ulrike Stange , Stefan Laufer , Cord Naujokat *
a
  Integrative Cancer Consulting, Aptos, CA, USA
b
  Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239, Heidelberg, Germany
c
  Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität, Tübingen and Tuebingen Center for Academic
Drug Discovery, Auf Der Morgenstelle 8, 72076, Tuebingen, Germany
d
  Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-69120, Heidelberg, Germany




A R T I C LE I N FO                                         A B S T R A C T

Keywords:                                                   Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future.
COVID-19                                                    Because a vaccine against the virus will not be available in the near future, we herein try to oﬀer a pharma-
SARS-CoV-2                                                  cological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with
Drugs                                                       and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of
Camostat
                                                            angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-
Chloroquine
Remdesivir
                                                            CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-
Lopinavir                                                   2. Further, chloroquine and hydroxychloroquine, and oﬀ-label antiviral drugs, such as the nucleotide analogue
Ritonavir                                                   remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favi-
Favipiravir                                                 piravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and
Arbidol                                                     mortality of COVID-19 pandemic.
Phytochemicals




1. Introduction                                                                                  [6]. The coronavirus crown-like (“corona”) morphology is created by
                                                                                                 transmembrane spike glycoproteins (S proteins) that form homotrimers
    The outbreak of coronavirus SARS-CoV-2 in Wuhan, China in                                    protruding from the viral surface [7]. The S proteins of SARS-CoV and
December 2019, the cause of Corona Virus Disease of 2019 (COVID-19),                             SARS-CoV-2 display structural homology and conserved ectodomains,
represents a pandemic threat to global health [1,2]. The WHO declared                            so earlier strategies employed to prevent binding of SARS-CoV to its
COVID-19 as a pandemic on March 11th 2020. The outbreak has spread                               host cell receptor angiotensin-converting enzyme 2 (ACE2) may be
to more than 185 countries with more than 3,200,000 conﬁrmed cases,                              relevant, since SARS-CoV-2 also employs ACE2 for cell entry [8,9].
more than 230,000 conﬁrmed deaths and more than 1,000,000 total                                  ACE2, an exopeptidase expressed on epithelial cells of the respiratory
recoveries worldwide as of May 1st 2 2020 [3]. Hundreds of millions of                           tract, may constitute a pharmacological target to limit cell entry of
lives have been aﬀected as a result of mandatory isolations/quar-                                SARS-CoV-2. The established antimalarial drugs chloroquine and hy-
antines. This pandemic has the potential to overwhelm national                                   droxychloroquine have been shown to inhibit terminal phosphorylation
healthcare systems, and have major consequences on global economy if                             of ACE2 and to elevate the pH in endosomes, respectively. Chloroquine
SARS-CoV-2 spread and virulence is not contained, or eﬀective treat-                             and hydroxychloroquine constitute candidate drugs against SARS-CoV-
ments are not developed.Coronaviruses are grouped into alpha, beta,                              2 infection and COVID-19 disease, and are now investigated for their
gamma, and delta classes. Coronaviruses can infect both humans and                               therapeutic eﬃcacy in international clinical trials with COVID-19 pa-
animals. The source of the beta coronavirus SARS-CoV-2 is believed to                            tients (i. e. SOLIDARITY Trial). The glycosylated S protein of SARS-
be bats, which carry the virus with no signs of disease [4]. Beta cor-                           CoV-2 is highly immunogenic to the host immune system, and murine
onaviruses caused earlier outbreaks of severe acute respiratory syn-                             polyclonal antibodies against SARS-Co-V S protein potently inhibit
dromes (SARS), including SARS-CoV (2002/2003 in Guangdong, China)                                SARS-CoV-2 S-mediated cell entry, indicating that cross-neutralizing
and Middle East Respiratory Syndrome virus MERS-CoV (2012 in Saudi                               antibodies targeting conserved S epitopes can be elicited upon vacci-
Arabia) [5]. Beta coronaviruses are pathogenic for humans and have a                             nation [9]. Similar to the earlier SARS and MERS beta coronaviruses,
single stranded RNA genome, encapsulated by a membrane envelope                                  SARS-CoV-2 primarily infects alveolar epithelial cell of the lung,


    ⁎
        Corresponding author.
        E-mail address: prof.naujokat@gmx.de (C. Naujokat).

https://doi.org/10.1016/j.phrs.2020.104859
Received 27 March 2020; Received in revised form 20 April 2020; Accepted 22 April 2020
Available online 29 April 2020
1043-6618/ © 2020 Elsevier Ltd. All rights reserved.


D.L. McKee, et al.                                                                                                    Pharmacological Research 157 (2020) 104859


leading to a severe bilateral peripheral pneumonia with ground glass              guanidinobenzoyloxy)-phenylacetate] methanesulfate and camostat
opacity in CT images (COVID-19 disease), with a mortality rate of 2 %             mesilate (Foipan™), alternatively termed camostat mesylate, (NI-03),
to 5 % [10]. SARS-CoV-2 also can contribute to multiple organ failure,            (CAS number: 59721−28-7), constitute synthetic serine protease in-
aﬀecting heart, liver, kidney, central nervous system and gastro-                 hibitors that were developed decades ago for the treatment of oral
intestinal tract [11]. Epidemiology thus far suggests that SARS-CoV-2 is          squamous cell carcinoma [23,24], dystrophic epidermolysis [25], exo-
more contagious than SARS-CoV or MERS-CoV [12]. Multiple me-                      crine pancreatic enzyme inhibition [26,27], and chronic pancreatitis
chanisms now identiﬁed in the infective and replication processes of              [28–31]. Camostat mesilate (NI-03) is manufactured as an oral drug by
SARS-CoV-2 oﬀer targets for pharmacological interventions. Infection              Nichi-Iko Pharmaceutical Co., Ltd., and Ono Pharmaceutical, Japan,
of pneumocytes, macrophages and pulmonary mast cells requires viral S             with a three times daily dose recommendation of 100 mg–300 mg
protein. This invasion process which involves attachment of S protein to          [30,31]. In a clinical trial investigating camostat mesilate against dys-
the ACE2 receptor is facilitated by host cell derived serine protease             pepsia associated with non-alcoholic mild pancreatic disease, 95 pa-
TMPRSS2 [8]. Agents that inhibit TMPRSS2, such as camostat mesilate,              tients received 200 mg camostat mesilate three times daily for 2 weeks
may be useful in blocking viral host cell entry. After host cell entry, the       and showed only mild, but no severe adverse eﬀects [28], indicating
viral single-stranded positive RNA is released for replication of virus           that camostat mesilate is a well-tolerated drug.
RNA and translation of virus polyproteins that are ﬁnally cleaved into
mature eﬀector proteins by virus proteases [13]. The S protein inter-             2.1.2. Nafamostat mesilate (Buipel™)
action with ACE2 on host cell cytoplasmic membrane initiates viral                    Nafamostat mesilate (Buipel™), (6-amidino-2-naphthyl-4-guanidino
infection. Strategies capable of disrupting S protein interaction with            benzoate-dimethanesulfonate) (FUT-175), (CAS number: 81525−10-
ACE2 could be of signiﬁcant therapeutic value, because the binding                2), is a clinical proven and synthetic serine protease inhibitor approved
aﬃnity of SARS-CoV-2 S protein to ACE2 is 10−20-fold higher than for              in Japan for the treatment of acute pancreatitis, disseminated in-
the S protein of SARS-CoV which may contribute to the higher con-                 travascular coagulation and for anticoagulation in extracorporeal cir-
tagiousness of SARS-CoV-2 as compared to SARS-CoV [12]. Although                  culation [32–34]. In a screening approach of about 1100 drugs ap-
SARS-CoV and SARS-CoV-2 have only 79 % genomic sequence simi-                     proved by the FDA, nafamostat mesilate has been identiﬁed to inhibit
larity, they share a highly conserved receptor binding domain for their           MERS-CoV S protein-mediated viral membrane fusion with TMPRSS2-
S proteins [1]. There is also potential for targeting other highly con-           expressing lung Calu-3 host cells by inhibiting TMPRSS2 protease ac-
served proteins associated with SARS-CoV and SARS-Co-V-2, including               tivity [35]. Since the S proteins of MERS-Cov and SARS-CoV-2 share
RdRp and 3Clpro (also termed Mpro), which share over 95 % similarity              considerable amino acid sequence homology [1,9], nafamostat mesilate
between the two viruses, despite only 79 % genomic sequence sharing.              may also inhibit cell entry of SARS-CoV-2. In cell culture experiments
RdRp is an RNA-dependent RNA polymerase required for replicating                  with simian Vero E6 cells infected with SARS-CoV-2, nafamostat me-
the viral genome within the host cell. 3Clpro and Plpro are both viral            silate was shown to be inhibitive against SARS-CoV-2 infection at EC50
proteases which break down viral polyprotein into functional units                of 22.50 μM [36], suggesting that nafamostat mesilate is able to prevent
within host cells that are ﬁnally assembled into new viruses. The 3Clpro          SARS-CoV-2 infection. In a multicenter, randomized, open-label, phase
sequences between the two viruses are 96 % similar, the Plpro sequence            2 trial in 19 patients with severe acute pancreatitis, nafamostat mesilate
identity is 83 %, and their active sites show a high degree of con-               was administered intravenously at a daily dose of 240 mg for 5 days
servation [14]. Drugs that have recently been shown to target MERS-               without severe adverse eﬀects [34].
CoV in mice [15], and to inhibit Ebola virus RdRp and SARS-CoV-2
proteases in humans, such as remdesivir and ritonavir/lopinavir, also             2.2. Inhibitors of angiotensin-converting enzyme 2 (ACE2) and
constitute candidate drugs against SARS-CoV-2 and are now in-                     antimalarial/parasiticide drugs
vestigated for their therapeutic eﬃcacy in COVID-19 patients in 2 in-
ternational clinical trials (SOLIDARITY Trial and DisCoVeRy Trial).                   SARS-CoV and related coronaviruses directly interact via their S
Finally, certain phytochemicals and natural products with high anti-              proteins with angiotensin-converting enzyme 2 (ACE2), a host cell
viral activity should be considered for treatment of SARS-CoV-2 infec-            exopeptidase and metallocarboxypeptidase that catalyses the conver-
tion and COVID-19 disease.                                                        sion of angiotensin I to the nonapeptide angiotensin and the conversion
                                                                                  of angiotensin II to angiotensin 1–7, to initiate S protein-mediated cell
2. Inhibitors of cell entry of SARS-CoV-2                                         entry [37–39]. It was demonstrated recently that also SARS-CoV-2 uses
                                                                                  ACE2 as a receptor for S protein-driven host cell entry [8,9]. Therefore,
2.1. Inhibitors of TMPRSS2 serine protease                                        ACE2 constitute a molecular target to inhibit cell entry of SARS-CoV-2.
                                                                                  Unfortunately, ACE inhibitors as standard drugs for the treatment of
    Results from previous studies reveal that diverse viruses, including          hypertension and chronic heart failure fail to inhibit ACE2 [40], but a
Ebola virus, SARS-coronavirus (SARS-CoV), MERS-coronavirus (MERS-                 number of other drugs and compounds have been shown to inhibit
CoV) and inﬂuenza virus employ host cell proteases for activation of              ACE2.
their envelope glycoproteins [16–18]. Cleavage and activation of the
spike protein (S protein) of SARS-CoV that is required for membrane               2.2.1. Chloroquine phosphate and hydroxychloroquine
fusion and host cell entry is mediated by transmembrane protease/                     Chloroquine phosphate (Resochin™) and its derivative hydroxy-
serine subfamily member 2 (TMPRSS2), an airway and alveolar cell                  chloroquine (Quensyl™, Plaquenil™, Hydroquin™, Dolquine™,
serine protease [19–21]. Pöhlmann and coworkers recently demon-                   Quinoric™) have been used for decades for the prophylaxis and treat-
strated that SARS-CoV-2 also employs TMPRSS2 for SARS-CoV-2 S                     ment of malaria and for the treatment of chronic Q fever and various
protein priming and S protein-driven cell entry [8]. Using camostat               autoimmune diseases [41], and have recently been demonstrated as
mesilate, a clinically proven and commercial serine protease inhibitor            potential broad-spectrum antiviral drugs [42,43]. Chloroquine phos-
that partially blocks infection by SARS-CoV and HCoV-NL63 in HeLa                 phate inhibits terminal phosphorylation of ACE2, and hydroxy-
cell expressing ACE2 and TMPRSS2 [22], it was shown that inhibition               chloroquine elevates the pH in endosomes which are involved in virus
of TMPRSS2 in human lung Calu-3 cells by camostat mesilate sig-                   cell entry [44,45], both mechanisms constitute relevant antiviral me-
niﬁcantly reduced infection with SARS-CoV-2 [8].                                  chanisms of chloroquine and hydroxychloroquine. In vivo, hydroxy-
                                                                                  chloroquine is metabolized into chloroquine. Chloroquine phosphate
2.1.1. Camostat mesilate (Foipan™)                                                has previously been shown to inhibit SARS-CoV infection and spread in
    Camostat, (FOY-305), [N,N-dimethylcarbamoylmethyl                4-(4-        vitro [44,46], and results from very recent studies reveal that

                                                                              2


D.L. McKee, et al.                                                                                                                                                                                                                                                       Pharmacological Research 157 (2020) 104859


                                                                                                                                                                                                                                      chloroquine phosphate and, more eﬀectively, hydroxychloroquine also




                                                                        [47,49,50,51]

                                                                                                                             [36,77,82,83]
                                                                        [34,35,36]




                                                                                                                             [95,96,98]
                                                                                                                                                                                                                                      inhibit replication of SARS-CoV-2 in simian Vero cells [46,47]. By using




                                                                                                                             [111,112]
                                                           Reference




                                                                        [48,49]
                                                                        [8,28]                                                                                                                                                        a physiologically-based pharmacokinetic model for chloroquine phos-




                                                                                                                                                                [122]
                                                                                                                                                                                                                                      phate and hydroxychloroquine in human lung ﬂuid, it was demon-
                                                                                                                                                                                                                                      strated that the concentrations of hydroxychloroquine recommended
                                                                        400 mg loading dose twice daily at day 1, 200 mg twice daily for 4 days, or 600 mg
                                                                                                                                                                                                                                      for treatment of SARS-CoV-2 infection comprise an oral loading dose of
                                                                        200 mg loading dose at day 1, 100 mg for 9−13 days, peroral or intravenous
                                                                                                                                                                                                                                      400 mg twice daily at day 1, followed by an oral maintenance dose of
                                                                        400 mg lopinavir and 100 mg ritonavir twice daily, for 14 days, peroral                                                                                       200 mg twice daily for 4 days [47]. These results were deduced from in
                                                                                                                                                                                                                                      vitro data obtained from SARS-CoV-2-infected Vero cells treated with
                                                                                                                                                                                                                                      hydroxychloroquine [47]. A recent pilot trial conducted in more than
                                                                                                                                                                6000 mg loading dose at day 1, 2, 400 mg for days 2−10, peroral
                                                                                                                                                                                                                                      10 hospitals in Wuhan, Jingzhou, Guangzhou, Bejing, Shanghai,
                                                                                                                                                                                                                                      Chongqing and Ningbo, China, with more than 100 patients with
                                                                                                                                                                                                                                      COVID-19 disease demonstrated that treatment with chloroquine
                                                                                                                                                                                                                                      phosphate is superior to control treatment in inhibiting the exacerba-
                                                                        250 mg daily until clinical convalescence, peroral




                                                                                                                                                                                                                                      tion of pneumonia, improving lung imaging ﬁndings, promoting la-
                                                                        200 mg three times daily, for 2 weeks, peroral




                                                                                                                                                                                                                                      boratory virus-negative conversion, and shortening the course of
                                                                        400 mg three times daily, for 9 days, peroral




                                                                                                                                                                                                                                      COVID-19 disease [48]. Chloroquine phosphate should be administered
                                                                        for 6 days, or 400 mg for 5 days, peroral




                                                                                                                                                                                                                                      as an oral daily dose of 250 mg until clinical convalescence [49]. Thus,
                                                                                                                                                                                                                                      in view of these results and the urgent clinical demand regarding SARS-
                                                                        240 mg daily, for 5 days, peroral




                                                                                                                                                                                                                                      CoV-2/COVID-19 pandemia, chloroquine phosphate should be re-
                                                                                                                                                                                                                                      commended to treat COVID-19 associated pneumonia in larger popu-
                                                                                                                                                                                                                                      lations [48]. A recent open-label non-randomized clinical trial con-
                                                                                                                                                                                                                                      ducted in March 2020 in France with 20 COVID-19 patients treated
                                                                                                                                                                                                                                      with daily 600 mg hydroxychloroquine for 6 days demonstrated at day
                                                                                                                                                                                                                                      6 a negative viral load (negative nasopharyngeal PCR) in 57 % of the
                                                                                                                                                                                                                                      hydroxychloroquine-treated patients, as compared to negative viral
                                                           Dosage




                                                                                                                                                                                                                                      load in 12.5 % of untreated COVID-19 patients (control group, n = 16)
                                                                                                                                                                                                                                      [50]. In a randomized clinical trial conducted in February 2020 in
                                                                                                                                                                                                                                      Wuhan, China, sixty two COVID-19 patients were randomized to re-
                                                                                                                             Membrane fusion, clathrin-mediated




                                                                                                                                                                                                                                      ceive either daily 400 mg hydroxychloroquine for 5 days (n = 31) or no
                                                                                                                                                                                                                                      pharmacological treatment (n = 31) [51]. Improvement and absorp-
                                                                                                                                                                                                                                      tion of pneumonia as analyzed in chest CT at day 6 was observed in
                                                                        Endosome, pH elevation




                                                                                                                                                                                                                                      80.6 % of the hydroxychloroquine-treated patients vs. 54.8 % in the
                                                                                                                                                                                                                                      untreated patients [51]. The results from these small studies therefore
                                                                                                                                                                                                                                      strongly suggest that hydroxychloroquine has therapeutic eﬃcacy in
                                                                                                                             Viral proteases




                                                                                                                                                                                                                                      COVID-19 disease. Thus, a considerable number of clinical trials in-
                                                                                                                             endocytosis
                                                                        TMPRSS2
                                                                        TMPRSS2




                                                                                                                                                                                                                                      vestigating therapeutic eﬃcacy of chloroquine phosphate and hydro-
                                                           Target




                                                                        ACE2



                                                                                                                             RdRp




                                                                                                                             RdRp




                                                                                                                                                                                                                                      xychloroquine in patients with SARS-CoV-2 infection and COVID-19
                                                                                                                                                                                                                                      disease have been initiated in China, Great Britain, Spain and Thailand
                                                                                                                                                                                                                                      [52–56].
                                                                        Serine protease inhibitor
                                                                        Serine protease inhibitor




                                                                                                                                                                                                                                      2.2.2. Cepharanthine/selamectin/meﬂoquine hydrochloride
                                                                        Antimalarial drug
                                                                        Antimalarial drug




                                                                                                                                                                                                                                          The triple combination of cepharanthine (an anti-inﬂammatory al-
                                                                                                                             Antiviral drug
                                                                                                                             Antiviral drug
                                                                                                                             Antiviral drug

                                                                                                                                                                Antiviral drug




                                                                                                                                                                                                                                      kaloid from Stephania cepharantha Hayata), (CAS number: 48,104,902),
                                                                                                                                                                                                                                      selamectin (an avermectin isolated from Streptomyces avermitilis and
                                                           Class




                                                                                                                                                                                                                                      used as an anti-helminthic and parasiticide drug in veterinary medi-
                                                                                                                                                                                                                                      cine), (CAS number. 220119−17-5), and meﬂoquine hydrochloride
                                                                                                                                                                                                                                      (Lariam™, used for the prophylaxis and treatment of malaria) [57–59]
 Oﬀ-label drugs against SARS-CoV-2 and COVID-19 disease.




                                                                                                                                                                                                                                      has recently been shown to inhibit infection of simian Vero E6 cells
                                                                       Hydroxychloroquine (QuensylTM, PlaquenilTM, HydroquinTM,




                                                                                                                                                                                                                                      with pangolin coronavirus GX_P2V/2017/Guangxi (GX_P2V), whose S
                                                                                                                                                                                                                                      protein shares 92.2 % amino acid identity with that of SARS-CoV-2
                                                                                                                                                                                                                                      [60]. Further, it was demonstrated that GX_P2V also uses ACE2 as the
                                                                                                                                                                                                                                      receptor for viral cell entry [60]. Two libraries of 2406 clinically ap-
                                                                                                                                                                                                                                      proved drugs were screened for their ability to inhibit cytopathic eﬀects
                                                                                                                                                                                                                                      on Vero E6 cells by GX_P2V, and only the combination of cephar-
                                                                       Chloroquine phosphate (ResochinTM)




                                                                                                                                                                                                                                      anthine, selamectin and meﬂoquine hydrochloride was identiﬁed as
                                                                                                                                                                                                                                      candidate drug combination against SARS-CoV-2 infection [60].
                                                                       Nafamostat mesilate (BuipelTM)




                                                                       Lopinavir/ritonavir (KaletraTM)
                                                                       Camostat mesilate (FoipanTM)




                                                                           DolquineTM, QuinoricTM)




                                                                                                                                                                                                                                      2.2.3. Experimental inhibitors of ACE2
                                                                       Umifenovir (ArbidolTM)

                                                                                                                                                             Favipiravir (AviganTM)




                                                                                                                                                                                                                                          Shortly after the identiﬁcation of the angiotensin-converting en-
                                                                                                                                                                                                                                      zyme 2 (ACE2), a metallocarboxypeptidase that mediates various car-
                                                                                                                                                                                                                                      diovascular and renal functions, peptide inhibitors of the enzyme were
                                                                       Remdesivir




                                                                                                                                                                                                                                      developed by selection of constrained peptide libraries displayed on
                                                                                                                                                                                                                                      phage [61]. The most potent inhibitor, termed DX600, with the amino
 Table 1


                                                           Drug




                                                                                                                                                                                                                                      acid sequence of Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2 had a
                                                                                                                                                                                                                                      Ki of 2.8 nm and an IC50 of 10.1 μM [61]. Subsequent experimental

                                                                                                                                                                                                                                  3


D.L. McKee, et al.                                                                                                         Pharmacological Research 157 (2020) 104859




Fig. 1. Structural formulas of candidate drugs against SARS-CoV-2 and COVID-19.
(A) camostat, (B) nafamostat, (C) chloroquine, (D) hydroxychloroquine, (E) remdesivir (F) lopinavir, (G) ritonavir, (H) umifenovir, (I) favipiravir


studies in mice and in human cell lines revealed that DX600 is a potent              cell entry. Moreover, the phytochemical nicotianamine (CAS number:
ACE2 inhibitor speciﬁc for only human ACE2 [62,63]. Other small-                     34441−14-0), a metal chelator ubiquitously present in higher plants
peptide and tripeptide inhibitors have been developed for potent and                 [71], was identiﬁed in high concentrations in soybean, and was shown
selective inhibition of human ACE2 and inhibition of SARS-CoV cell                   as a potent inhibitor of human ACE2 with an IC50 of 84 nM [72]. Be-
entry in vitro [64–66]. More recently, synthetic small-molecule in-                  cause dietary phytochemicals as naturally occurring compounds display
hibitors of human ACE2, including MLN-4760 (CAS number:                              a wide safety proﬁle and less pharmacological side eﬀects [73], nico-
305335−31-3) [63,67], N-(2-aminoethyl)-1 aziridine-ethanamine [68]                   tianamine constitutes a candidate drug for ACE2 inhibition and thus
and the TNF-α converting enzyme (TACE) small-molecule inhibitor                      blockade of SARS-CoV-2 cell entry. Finally, a recent study demonstrates
TAPI-2 that blocks SARS-CoV S protein-induced shedding of ACE2                       that a clinical-grade soluble recombinant human ACE2 protein
[69,70] have been developed for experimental inhibition of SARS-CoV                  (hrsACE2) inhibits attachment of SARS-CoV-2 to simian Vero-E 6 cells,

                                                                                 4


D.L. McKee, et al.                                                                                                     Pharmacological Research 157 (2020) 104859


and inhibits infection of engineered human capillary organoids and               3.2. Lopinavir/ritonavir (Kaletra™)
kidney organoids by SARS-CoV-2 isolated from a nasopharyngeal
sample of a patient with conﬁrmed COVID-19 disease [74], suggesting                  Lopinavir (ABT-378) is a highly potent inhibitor of the human im-
that hrsACE2 can block host cell entry of SARS-CoV-2 and early stages            munodeﬁciency virus (HIV) protease essential for intracellular HIV
of SARS-CoV-2 infections.                                                        assembly that was developed in 1998 to circumvent HIV resistance
                                                                                 towards the protease inhibitor ritonavir (ABT-538), caused by mutation
                                                                                 of valine at position 82 (Val 82) in the active site of HIV protease in
3. Inhibitors of replication, membrane fusion and assembly of                    response to ritonavir therapy [92]. Because the metabolism of lopinavir
SARS-CoV-2                                                                       is strongly inhibited by ritonavir, concomitant oral administration of
                                                                                 lopinavir and ritonavir exceeded the in vitro antiviral EC50 of lopinavir
3.1. Remdesivir                                                                  by > 50-fold after 8 h in rat, dog, and monkey plasma [92]. Coadmi-
                                                                                 nistration of 400 mg lopinavir with 50 mg ritonavir enhanced in
    Remdesivir (GS-5734), (CAS number: 1809249−37-3), is a novel                 healthy human volunteers the area under the concentration curve of
small-molecule adenine nucleotide analogue antiviral drug that has               lopinavir in plasma by 77-fold over that observed after dosing with
shown eﬃcacy against Ebola virus in rhesus monkeys. Once-daily in-               lopinavir alone, and mean concentrations of lopinavir exceeded the
travenous administration of 10 mg kg(-1) remdesivir for 12 days re-              EC50 for > 24 h [92]. Therefore, the combination of lopinavir and ri-
sulted in profound suppression of Ebola virus replication and protected          tonavir (Kaletra™) has been established as an eﬀective oral drug for the
100 % of Ebola virus-infected animals against lethal disease [75]. Re-           treatment of HIV-infected individuals when used in combination with
mdesivir displays antiviral activity against other single stranded RNA           other antiretroviral agents [93,94].An initial study in 2003 demon-
viruses, including ﬁloviruses, pneumoviruses, paramyxoviruses, and the           strated that lopinavir at 4 μg/mL inhibited the cytopathic eﬀect in a
coronaviruses MERS-CoV and SARS-CoV [76–78]. Remdesivir is a                     plaque reduction assay with fetal rhesus kidney-4-cells infected with
prodrug that is metabolized into its active form GS-441524, an adenine           SARS-CoV (HKU-39,849 isolate) [95]. In this study, newly diagnosed
nucleotide analogue that interferes with the activity of viral RNA-de-           SARS patients infected with SARS-CoV were treated with the combi-
pendent RNA polymerase (RdRp) and that promotes evasion of proof-                nation of lopinavir (400 mg)/ritonavir (100 mg) orally every 12 h for
reading by viral exoribonuclease, leading to inhibition of viral RNA             14 days. At day 21, SARS patients treated with lopinavir/ritonavir had
synthesis [78]. Remdesivir acts early in infection, and decreases viral          a milder disease course in terms of diarrhea, recurrence of fever, wor-
RNA levels in a dose-dependent manner that parallels impairment of               sening of chest radiographs and reduction of viral load, compared to a
viral load in vitro [78]. These and related mechanisms of action of re-          historical control group [95]. In a nonhuman primate model of common
mdesivir have been demonstrated in vitro for SARS-CoV [78], Ebola                marmosets infected with MERS-CoV, lopinavir/ritonavir-treated ani-
virus [79] and MERS-CoV [80]. A recent study demonstrates in cell                mals displayed an improved clinical outcome compared to untreated
culture experiments with simian Vero E6 cells infected with SARS-CoV-            animals, with improved weight loss, lung imaging and pathological
2 that remdesivir is inhibitive against SARS-CoV-2 infection at EC90 of          ﬁndings, and lower mean viral loads in necropsied lung and extra-
1.76 μM, a concentration achieved in vivo in nonhuman primate models             pulmonary tissues [96]. In response to these ﬁndings, an ongoing ran-
[36]. It was further shown that remdesivir eﬃciently inhibited SARS-             domized control trial (MIRACLE Trial) was initiated to determine the
CoV-2 infection of human liver cancer Huh-7 cells, which are sensitive           therapeutic eﬃcacy of lopinavir/ritonavir combined with interferon β-
to SARS-CoV-2 infection [36]. The prophylactic and therapeutic eﬃ-               1b in patients infected with MERS-CoV [97]. In a recent randomized,
cacy of remdesivir have been shown recently in a nonhuman primate                controlled, open-label trial involving 199 hospitalized adult patients in
model (rhesus monkeys) of MERS-CoV infection [81]. Prophylactic                  Wuhan/China with conﬁrmed SARS-CoV-2 infection and COVID-19
treatment of rhesus monkeys with remdesivir initiated 24 h prior to              pneumonia, oral administration of twice daily 400 mg lopinavir and
inoculation of MERS-CoV completely prevented virus-induced disease,              100 mg ritonavir for 14 days revealed rather disappointing results,
inhibited virus replication in respiratory tissues, and prevented the            compared to the control group (100 patients) receiving standard-care
occurrence of lung lesions [81]. Remdesivir treatment of rhesus mon-             treatment [98]. Treatment with lopinavir/ritonavir was not associated
keys 12 h after inoculation of MERS-CoV also provided a signiﬁcant               with a diﬀerence from standard care in the time to clinical improve-
clinical beneﬁt, with reduction in clinical signs, reduced virus replica-        ment, and mortality at 28 days was similar in the lopinavir/ritonavir
tion in respiratory tissues, and decreased occurrence and severity of            group and the standard-care group [98]. Moreover, treatment with
lung lesions [81]. From a randomized, controlled trial of Ebola virus            lopinavir/ritonavir treatment did not reduce viral RNA loads or dura-
therapeutics that was conducted in response to the Ebola virus outbreak          tion of viral RNA detectability as compared with standard supportive
in the Democratic Republic of Congo in August 2018, there are human              care. SARS-CoV-2 RNA was still detected in 40.7 % of the patients in the
safety data available for remdesivir. In a subgroup of 175 patients              lopinavir/ritonavir group at the end of the trial at day 28 [98]. How-
treated with remdesivir (loading dose of 200 mg on day 1, followed by a          ever, the numbers of lopinavir/ritonavir recipients who had serious
maintenance dose of 100 mg for 9−13 days), 9 patients experienced                complications (acute kidney injury and secondary infections) or re-
serious adverse events [82], indicating that remdesivir is a relatively          quiring noninvasive or invasive mechanical ventilation for respiratory
safe drug. A recent clinical trial with remdesivir for a compassionate use       failure were fewer than in those not receiving lopinavir/ritonavir
to 53 COVID-19 patients receiving oxygen support or mechanical ven-              treatment [98]. These results and observations require additional stu-
tilation due to an oxygen saturation of 94 % or less demonstrated that           dies to determine whether treatment with lopinavir/ritonavir given at a
intravenous treatment with 200 mg remdesivir at day 1, followed by               certain disease stage can reduce some complications in COVID-19 pa-
100 mg daily for 9 days, resulted in clinical improvement in 36 of the           tients [98]. Finally, clinical trials with lopinavir/ritonavir in COVID-19
53 patients (68 %) [83]. However, the mortality rate was 18 % among              patients have been initiated recently in China [99–102], Hong Kong
patients receiving invasive ventilation and 5% among patients not re-            [103], Republic of Korea [104], and in Europe (DisCoVeRy Trial), in-
ceiving invasive ventilation [83], suggesting that remdesivir constitutes        vestigating remdesivir, lopinavir/ritonavir, and lopinavir/ritonavir plus
a therapeutic option for COVID-19 patients not receiving invasive                interferon β-1a [91].
ventilation. Based on the experimental and clinical results described
above, clinical trials with remdesivir in COVID-19 patients have been            3.3. Umifenovir (Arbidol™)
initiated recently, in China [84,85], the USA, Republic of Korea and
Singapore [86], in the USA, Hong Kong, Republic of Korea, Singapore                 Umifenovir (Arbidol™), (ethyl-6-bromo-4-[(dimethylamino)me-
and Taiwan [87,88], in the USA [89], and in France [90,91].                      thyl]-5-hydroxy-1-methyl-2 [(phenylthio)methyl]-indole-3-carboxylate

                                                                             5


D.L. McKee, et al.                                                                                                     Pharmacological Research 157 (2020) 104859


hydrochloride monohydrate), (CAS number: 131707−25-0), is a small                 unligated SARS-CoV-2 3Clpro and its complex with α-ketoamides de-
indole-derivate molecule manufactured by JSC Pharmstandard, Russia                signed as speciﬁc inhibitors of 3Clpro were reported [126]. Two pyr-
[105]. Umifenovir prevents viral host cell entry by inhibition of                 idine-containing α-ketoamides, designated 13a and 13b, displayed fa-
membrane fusion of viral envelope and host cell cytoplasmic membrane              vorable pharmacokinetic properties in mice and were detected at
via inhibition of clathrin-mediated endocytosis, thereby preventing               suﬃcient concentrations in lung tissue and broncheo-alveolar lavage
virus infection [106–108]. Umifnovir is licensed in Russia and China for          ﬂuid within 4 hours–24 hours after subcutaneous administration, de-
oral prophylaxis and treatment of infections with inﬂuenza A and B                monstrating lung tropism of the compounds [126]. Besides sub-
viruses and other respiratory viruses [105], and has been demonstrated            cutaneous administration, inhalation of nebulized 13b by mice resulted
to inhibit in vitro infection with globally prevalent pathogenic viruses,         in high and long-lasting (24 h) concentrations in lung tissue, without
including hepatitis C virus, hepatitis B virus, Ebola virus, Lassa virus,         any adverse eﬀects [126], pointing out a role of pyridine-containing α-
human herpesvirus 8, poliovirus, and vesicular stomatitis virus                   ketoamides in COVID-19 therapy. In a recent study that employed
[109,110], ultimately deﬁning umifenovir as a broad-spectrum anti-                combined structure-assisted drug design, virtual drug screening and
viral drug. In a clinical pilot trial conducted in January 2020 in Wuhan,         high-throughput screening, a mechanism-based inhibitor of 3Clpro,
China, 36 patients with COVID-19 disease received 400 mg umifenovir               termed N3, was identiﬁed by computer-aided drug design [127]. N3, a
three times a day for 9 days; 31 untreated COVID-19 patients served as            Michael acceptor inhibitor that can inhibit the 3Clpros of SARS-CoV
a control group [111]. In this trial, treatment with umifenovir showed a          and MERS-CoV, was shown to form a covalent bond with and to be an
tendency to reduce viral load determined by RT-PCR, and decreased                 irreversible inhibitor of SARS-CoV-2 3Clpro [127]. Further, in a high-
mortality (0 % vs. 16 %), as compared to the control group [111]. In a            throughput screening approach for identifying inhibitors of SARS-CoV-
single-center, retrospective cohort study conducted in February 2020 in           2 3Clpro, ebselen, an organoselenium compound with anti- in-
Guangdong, China, 16 patients with COVID-19 disease received orally               ﬂammatory, anti-oxidant and cytoprotective properties, was identiﬁed
200 mg umifenovir every 8 h plus lopinavir (400 mg)/ritonavir (100                [127]. In a plaque-reduction assay with simian Vero cells infected with
mg) every 12 h for 5–21 days; seventeen COVID-19 patients received                SARS-CoV-2, N3 and ebselen displayed antiviral and cell protection
lopinavir (400 mg)/ritonavir (100 mg) every 12 h and served as a                  eﬃcacy at EC50 values of 16.77 μM and 4.67 μM, respectively [127],
control group [112]. After 14 days of treatment, detection of                     ultimately demonstrating their antiviral potential against SARS-CoV-2.
SARS−COV-2 by RT-PCR was negative in 94 % of the umifenovir-
treated patients vs. 53 % in the control group, and the chest computed            4. Phytochemicals and natural products targeting coronaviruses
tomography scans were improving for 69 % of the umifenovir-treated
patients vs. 29 % in the control group [112]. In view of these promising              Natural products can inhibit various steps in viral infection and
clinical results, clinical trials with umifenovir alone or in combination         replication, and many of them have broad-spectrum antiviral eﬀects,
with lopinavir/ritonavir, chloroquine phosphate or carrimycin have                the mechanisms of which have not been fully characterized. They also
been recently initiated in China [113–116].                                       can function as immunomodulators, suppressing inﬂammatory reaction
                                                                                  responsible for the major morbidity and mortality of SARS-CoV-2 in-
3.4. Favipiravir (Avigan™)                                                        fection. Phytochemicals, especially ﬂavonoids, which are widely dis-
                                                                                  tributed in food plants and botanicals, have been shown to interfere
    Favipiravir     (Avigan™),    (T-705),     (6-ﬂuoro-3-hydroxy-2-pyr-          with NLRP3 inﬂammasome signaling [128]. The respiratory distress
azinecarboxamide), (CAS number: 259793−96-9), is an oral pyr-                     syndrome associated with SARS coronaviruses develops in part due to
azinecarboxamide derivative and guanine analogue developed by                     viral activation of the NLRP3 inﬂammasome within activated macro-
Toyama Chemical, Japan that selectively and potently inhibits the RNA-            phages and T helper-1 lymphocytes, which causes increased production
dependent RNA polymerase (RdRp) of RNA viruses and induces lethal                 of inﬂammatory cytokines [129]. Several ﬂavonoids that interfere with
RNA transversion mutations, thereby producing a nonviable virus                   activation of the NLRP3 inﬂammasome may modulate inﬂammatory
phenotype [117–119]. Favipiravir inhibits replication of a large                  response to SARS beta coronaviruses: luteolin [130], myricetin [131],
number of RNA viruses, including inﬂuenza A virus, ﬂavi-, alpha-, ﬁlo-,           apigenin [132], quercetin [133] kaempferol [134], baicalin [135], and
bunya-, arena- and noroviruses as well as West Nile virus, yellow fever           wogonoside [136]. These ﬂavonoids have been shown to be active
virus, foot-and-mouth-disease virus, Ebola virus and Lassa virus                  against a wide variety of viruses, via multiple mechanisms [137,138],
[120,121]. In a historically controlled, single-arm proof-of-concept trial        and are available as nutraceutical supplements at a daily dose ranging
conducted in response to the Ebola virus outbreak in September 2014 in            from 100 mg to 500 mg. Emodin (6-methyl-1,3,8-trihydroxyan-
Guinea, ninety nine adults with conﬁrmed positive semi-quantitative               thraquinone) (CAS number: 518−82-1) is an anthraquinone compound
Ebola virus RT-PCR (results expressed in “cycle threshold” [Ct]) were             found in various Chinese herbs and is also produced by many species of
treated with 6000 mg favipiravir at day 1, followed by 2400 mg favi-              fungi, including members of the genera Aspergillus, Pyrenochaeta, and
piravir at days 2−10 [122]. Patients were randomized by their Ct 20-              Pestalotiopsis. Emodin has been shown to inhibit the interaction of
value, and Ct 20 was adjusted to a RNA viral load of 7.7 log10 viral              SARS-CoV S protein with its receptor ACE2 in a dose-dependent manner
genome copies/mL. Mortality at day 14 of patients in the Ct ≥ 20-                 [139]. Resveratrol (trans-3,5,4′-trihydroxystilbene) (CAS number:
group (n = 55) was 20 %, whereas mortality in the CT < 20-group (n                501−36-0) is a stilbenoid and a natural polyphenol that is found in
= 44) was 91 % [122], suggesting that favipiravir is active in Ebola              high concentrations in the skins of red wine grapes (Vitis vinifera), in red
patients with high viral load. In response to this trial in Ebola patients,       wine and in sprouted peanuts (Arachis hypogaea). Resveratrol has been
clinical trials with favipiravir combined with a monoclonal antibody              demonstrated in vitro to inhibit MERS-CoV infection and to prolong
against the human interleukin-6 receptor, tocilizumab [123] or favi-              cellular survival after virus infection. Further, expression of MERS-CoV
piravir in combination with chloroquine phosphate and the viral                   nucleocapsid protein essential for virus replication as well as MERS-
neuramidase inhibitor oseltamivir [124] have been initiated recently in           CoV-induced host cell apoptosis are inhibited by resveratrol [140],
China.                                                                            suggesting that resveratrol may also be eﬀective against SARS-CoV-2
                                                                                  infection.
3.5. Inhibitors of SARS-CoV-2 3Clpro protease
                                                                                  5. Discussion and conclusion
   3Clpro (also termed Mpro) constitutes the main protease of beta
coronaviruses that is essential for processing of polyproteins translated           The emergence of the novel beta coronavirus SARS-CoV-2 from
from the viral RNA [125]. Recently, the X-ray structures of the                   Wuhan, Hubei province, China in December 2019 rapidly led to a

                                                                              6


D.L. McKee, et al.                                                                                                         Pharmacological Research 157 (2020) 104859


pandemic involving more than 3,200,000 infected persons and more                manuscript. AS and US wrote section 3 and prepared Table 1 and Fig. 1.
than 230,000 deaths in 185 countries as of May 1st 2020. SARS-CoV-2             SL ﬁnished the manuscript.
infection can cause a severe bilateral pneumonia that may progress to
multi-organ failure and death (COVID-19 disease), with a mortality rate         Declaration of Competing Interest
of 2 % to 5 % [10], though this may be inﬂated, due to inadequate
knowledge of the true number of cases, from countries which only test              None.
individuals with strong symptoms. Many cases appear to be mild or
even asymptomatic, so the true number of cases remains unknown.                 Acknowledgments
Since no vaccine will be available for large populations until the end of
2020, it is mandatory to identify approved oﬀ-label and experimental               We are grateful to all of the colleagues who have given critical
drugs against SARS-CoV-2 infection and COVID-19 disease. Such drugs             comments on this work.
may constitute inhibitors of TMPRSS2 and ACE2, established anti-
malarial drugs, antiviral drugs inhibiting viral RdRp, proteases and            References
virus/host cell membrane fusion as well as phytochemicals with anti-
viral activity, as reviewed herein. Besides preventive strategies against        [1] R. Lu, X. Zhao, J. Li, P. Niu, B. Wang, H. Wu, et al., Genomic characterisation and
SARS-CoV-2 infection practiced in many countries, such as quarantine                 epidemiology of 2019 novel coronavirus: implications for virus origins and re-
of conﬁrmed infected individuals, contact tracing by smartphone,                     ceptor binding, Lancet 395 (10224) (2020) 565–574.
                                                                                 [2] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A novel coronavirus
protection of individuals at high risk of infection, nationwide limited              from patients with pneumonia in China, N. Engl. J. Med. 383 (8) (2019) 727–733
curfew, and the urgent development and rapid provision of a vaccine,                 2020.
the WHO and the European Union recently and urgently initiated                   [3] https://coronavirus.jhu.edu/map.html Johns Hopkins University, USA, (2020).
                                                                                 [4] C. Li, Y. Yang, L. Ren, Genetic evolution analysis of 2019 novel coronavirus and
clinical trials to test remdesivir, chloroquine and hydroxychloroquine,              coronavirus from other species, Infect. Genet. Evol. 82 (2020) 104285.
lopinavir/ritonavir, and lopinavir/ritonavir plus interferon β-1a in             [5] S.J. Anthony, C.K. Johnson, D.J. Greig, S. Kramer, X. Che, H. Wells, et al., Global
COVID-19 patients worldwide in the SOLIDARITY Trial [141] and in                     patterns in coronavirus diversity, Virus Evol. 3 (1) (2017) vex012.
                                                                                 [6] S. Su, G. Wong, W. Shi, J. Liu, A.C.K. Lai, J. Zhou, et al., Epidemiology, genetic
the DisCoVeRy Trial [91]. Based on the experiences with infections by
                                                                                     recombination, and pathogenesis of coronaviruses, Trends Microbiol. 24 (6)
other viruses, such as HIV and inﬂuenza virus, post-exposure prophy-                 (2016) 490–502.
laxis with candidate drugs against SARS-CoV-2 infection may be ef-               [7] M.A. Tortorici, D. Veesler, Structural insights into coronavirus entry, Adv. Virus
                                                                                     Res. 105 (2019) 93–116.
fective in preventing disease after potential exposure to the virus or
                                                                                 [8] M. Hoﬀmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen,
positive test results, and in reducing the risk of secondary virus spread            et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
and COVID-19 disease. Candidate drugs for post-exposure prophylaxis                  clinically proven protease receptor, Cell (March 4) (2020), https://doi.org/10.
of SARS-CoV-2 infection could be clinically proven drugs such as ca-                 1016/j.cell.2020.02.052 pii: S0092-8674(20)30229-4.
                                                                                 [9] A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure,
mostat mesilate which prevents virus host cell entry by inhibiting                   function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell (March 6)
TMPRSS2 [8], and chloroquine phosphate which inhibits terminal                       (2020), https://doi.org/10.1016/j.cell.2020.02.058 pii: S0092-8674(20)30262-2.
phosphorylation of ACE2, or hydroxychloroquine which is metabolized             [10] Y.C. Wu, C.S. Chen, Y.J. Chan, The outbreak of COVID-19: an overview, J. Chin,
                                                                                     Med. Assoc. 83 (2) (2020) 217–220.
in vivo to chloroquine [44]. For the treatment of ordinary and severe           [11] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A novel coronavirus
COVID-19 pneumonia, and to lower the mortality rate of COVID-19                      from patients with pneumonia in China, N. Engl. J. Med. 382 (8) (2020) 727–733.
disease, the antiviral drugs remdesivir, favipiravir, umifenovir, and           [12] B. Tang, N.L. Bragazzi, Q. Li, S. Tang, Y. Xiao, J. Wu, An updated estimation of the
                                                                                     risk of transmission of the novel coronavirus (2019-nCov), Infect. Dis. Model. 5
lopinavir/ritonavir plus interferon β-1a should be administered, in                  (2020) 248–255.
particular after the consideration of (preliminary) results from the re-        [13] Y.M. Báez-Santos, S.E. St John, A.D. Mesecar, The SARS-coronavirus papain-like
cent ongoing clinical trials SOLIDARITY and DisCoVeRy [141,91] that                  protease: structure, function and inhibition by designed antiviral compounds,
                                                                                     Antiviral Res. 115 (2015) 21–38.
can be expected soon. Moreover, administration of the antiviral can-            [14] J.S. Morse, T. Lalonde, S. Xu, W.R. Liu, Learning from the past: possible urgent
didate drugs shortly after symptom onset may reduce infectiousness to                prevention and treatment options for severe acute respiratory infections caused by
other individuals by diminishing viral shedding in the respiratory se-               2019-nCoV, Chembiochem. 21 (5) (2020) 730–738.
                                                                                [15] T.P. Sheahan, A.C. Sims, S.R. Leist, A. Schäfer, J. Won, A.J. Brown, et al.,
cretions of SARS-CoV-2 infected patients that usually peaks at 5–6 days
                                                                                     Comparative therapeutic eﬃcacy of remdesivir and combination lopinavir, rito-
after symptom onset and lasts up to 14 days [142] (albeit shorter time               navir, and interferon beta against MERS-CoV, Nat. Commun. 11 (1) (2020) 222.
courses of nasopharyngeal viral shedding, peak: day 4, end: day 7, have         [16] S. Bertram, A. Heurich, H. Lavender, S. Gierer, S. Danisch, P. Perin, et al.,
been reported in mild cases of COVID-19 [143]), and prophylactic                     Inﬂuenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are ex-
                                                                                     pressed at multiple sites in human respiratory and gastrointestinal tracts, PLoS
treatment of contacts could reduce their risk of becoming infected.                  One 7 (4) (2012) e:35876.
Further, due to their wide safety proﬁle, less pharmacological side ef-         [17] Y. Zhou, P. Vedantham, K. Lu, J. Agudelo, R. Carrion, J.W. Nunneley, et al.,
fects and easy availability, phytochemicals, such as ﬂavonoids, emodin               Protease inhibitors targeting coronavirus and ﬁlovirus entry, Antiviral Res. 116
                                                                                     (2015) 76–84.
and resveratrol with postulated therapeutic eﬃcacy against SARS-CoV-            [18] M. Yamaya, Y. Shimotai, Y. Hatachi, N. Lusamba Kalonji, Y. Tando, Y. Kitajima,
2 infection and COVID-19 disease may be used by large populations for                et al., The serine protease inhibitor camostat inhibits inﬂuenza virus replication
pre- and post-exposure prophylaxis of SARS-CoV-2 infection and in                    and cytokine production in primary cultures of human tracheal epithelial cells,
                                                                                     Pulm. Pharmacol. Ther. 33 (2015) 66–74.
COVID-19 disease. Interestingly, a broad-spectrum antiviral drug, the           [19] S. Matsuyama, N. Nagata, K. Shirato, M. Kawase, M. Takeda, F. Tagushi, Eﬃcient
ribonucleoside analogue β-D-N4-hydroxycytidine (NHC, EIDD-1931),                     activation of the severe acute respiratory syndrome coronavirus spike protein by
with antiviral activity against SARS-CoV and MERS-CoV in mice and                    the transmembrane protease TMPRSS2, J. Virol. 84 (24) (2010) 12685-12664.
                                                                                [20] A. Shulla, T. Heald-Sargent, G. Subramanya, J. Zhao, S. Perlman, T. Gallagher, A
against SARS-CoV-2 in primary human airway epithelial cells has been                 transmembrane serine protease is linked to the severe acute respiratory syndrome
recently developed for the treatment of newly emerging coronavirus                   coronavirus receptor and activates virus entry, J. Virol. 85 (2) (2011) 873–882.
infections of the future [144].Finally, in the urgent case of the accel-        [21] I. Glowacka, S. Bertram, M.A. Müller, P. Allen, E. Soilleux, S. Pfeﬀerle, et al.,
                                                                                     Evidence that TMPRSS2 activates the severe acute respiratory syndrome cor-
erating COVID-19 pandemic, implementation of pharmacological anti-
                                                                                     onavirus spike protein for membrane fusion and reduces viral control by the hu-
viral prophylaxis and treatment of large populations has several re-                 moral immune response, J. Virol. 85 (9) (2011) 4122–4134.
quirements regarding high eﬃcacy, drug safety, high availability, and           [22] M. Kawase, K. Shirato, L. van der Hoek, F. Taguchi, S. Matsuyama, Simultaneous
economy.                                                                             treatment of human bronchial epithelial cells with serine and cysteine protease
                                                                                     inhibitors prevents severe acute respiratory syndrome coronavirus entry, J. Virol.
                                                                                     86 (12) (2012) 6537–6545.
Authors´ contributions                                                          [23] M. Ohkoshi, S. Fujji, Eﬀect of the synthetic protease inhibitor [N,N-di-
                                                                                     methylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methane-
                                                                                     sulfate on carcinogenesis by 3-methylcholanthrene in mouse skin, J. Natl. Cancer
    CN and DLM conceived the original idea and wrote large parts of the

                                                                            7


D.L. McKee, et al.                                                                                                                             Pharmacological Research 157 (2020) 104859


      Inst. 71 (5) (1983) 1053–1057.                                                                      open-label non-randomized clinical trial, Int. J. Antimicrob. Agents (March 20)
 [24] M. Ohkoshi, T. Oka, Clinical experience with a protease inhibitor [N,N-di-                          (2020) 105949, https://doi.org/10.1016/j.ijantimicag.2020.105949.
      methylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methane-                      [51]   Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han, D. Yan, et al., Eﬃcacy of hydroxy-
      sulfate for prevention of recurrence of carcinoma of the mouth and in treatment of                  chloroquine in patients with COVID-19: results of a randomized clinical trial,
      terminal carcinoma, J. Maxillofac. Surg. 12 (4) (1984) 148–152.                                     medRXiv (March 31) (2020), https://doi.org/10.1101/2020.03.22.20040758.
 [25] S. Ikeda, M. Manabe, T. Muramatsu, K. Takamori, H. Ogawa, Protease inhibitor                 [52]   Q. Zhang, Y. Wang, C. Qi, L. Shen, J. Li, Clinical trial analysis of 2019-nCoV
      therapy for recessive dystrophic epidermolysis bullosa. In vitro eﬀect and clinical                 therapy registered in China, J. Med. Virol. (February 28) (2020), https://doi.org/
      trial with camostat mesylate, J. Am. Acad. Dermatol. 18 (16) (1988) 1246–1252.                      10.1002/jmv.25733.
 [26] B. Göke, F. Stöckmann, R. Müller, P.G. Lankisch, W. Creutzfeld, Eﬀect of a speciﬁc           [53]   A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav, A systematic re-
      serine protease inhibitor on the rat pancreas: systemic administration of camostate                 view on the eﬃcacy and safety of chloroquine for the treatment of COVID-19, J.
      and exocrine pancreatic secretion, Digestion 30 (3) (1984) 171–178.                                 Crit. Care (March 10) (2020), https://doi.org/10.1016/j.jcrc.2020.03.005 pii:
 [27] G. Adler, A. Müllenhoﬀ, I. Koop, T. Bozkurt, B. Göke, C. Beglinger, et al.,                         S0883-9441(20)30390-7.
      Stimulation of pancreatic secretion in man by a protease inhibitor (camostate),              [54]   K.W. Chan, V.T. Wong, S.C.W. Tang, COVID-19: An update on the epidemiological,
      Eur. J. Clin. Invest. 18 (1) (2020).                                                                clinical, preventive and therapeutic evidence and guidelines of integrative
 [28] J.K. Sai, M. Suyama, Y. Kubokawa, Y. Matsumura, K. Inami, S. Watanabe, Eﬃcacy                       Chinese-Western medicine for the management of 2019 novel coronavirus disease,
      of camostat mesilate against dyspepsia associated with non-alcoholic mild pan-                      Am. J. Chin. Med. (Gard City N Y) (March 13) (2020) 1–26, https://doi.org/10.
      creatic disease, J. Gastroenterol. 45 (3) (2010) 335–341 1988 98-104.                               1142/S0192415X20500378.
 [29] H. Yamawaki, S. Futagami, K. Kaneto, S. Agawa, K. Higuchi, M. Murakami, et al.,              [55]   NCT04303507, ClinicalTrials.gov, (2020), Mar 11.
      Camostat mesilate, pancrelipase, and rabeprazole combination therapy improves                [56]   NCT04303299, ClinicalTrials.gov, (2020), Mar 11.
      epigastric pain in early chronic pancreatitis and functional dyspepsia with pan-             [57]   C. Bailly, Cepharanthine: An update of its mode of action, pharmacological
      creatic enzyme abnormalities, Digestion 99 (4) (2019) 283–292.                                      properties and medical applications, Phytomedicine 62 (September) (2019)
 [30] M.L. Ramsey, J. Nuttall, P.A. Hart, A phase 1/2 trial to evaluate the pharmaco-                     152956, https://doi.org/10.1016/j.phymed.2019.152956.
      kinetics, safety, and eﬃcacy of NI-03 in patients with Chronic pancreatitis: study           [58]   S. Khoja, N. Huynh, A.M.P. Warnecke, L. Asatryan, M.-W. Jakowec, D.L. Davies,
      protocol for a randomized controlled trial on the assessment of camostat treatment                  Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use
      in chronic pancreatitis (TACTIC), Trials 20 (1) (2019) 501.                                         disorders, Psychopharmacology (Berl.) 235 (6) (2018) 1697–1709.
 [31] NCT02693093, ClinicalTrials.gov, (2016), Feb 26.                                             [59]   M. Tickell-Painter, N. Maayan, R. Saunders, C. Pace, D. Sinclair, Meﬂoquine for
 [32] M. Iwako, Y. Ino, A. Motoyoshi, M. Ozeki, T. Sato, M. Kumuri, et al.,                               preventing malaria during travel to endemic areas, Cochrane Database Syst. Rev.
      Pharmacological studies of FUT-175, nafamostat mesilate. V. Eﬀects on the pan-                      10 (October 30) (2017), https://doi.org/10.1002/14651858.CD006491.pub4
      creatic enzymes and experimental acute pancreatitis in rats, Jpn. J. Pharmacol. 41                  CD006491.
      (2) (1986) 155–162.                                                                          [60]   H.H. Fan, L.Q. Wang, W.L. Liu, X.P. An, Z.D. Liu, X.Q. He, et al., Repurposing of
 [33] M. Hiraishi, Z. Yamazaki, K. Ichikawa, F. Kanai, Y. Idezuki, K. Onishi, et al.,                     clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-
      Plasma collection using nafamostat mesilate and dipyridamole as an antic-                           novel coronavirus (2019-nCoV) related coronavirus model, Chin. Med. J. (March
      oagulant, Int. J. Artif. Organs 11 (3) (1988) 212–216.                                              6) (2020), https://doi.org/10.1097/CM9.0000000000000797.
 [34] M. Hirota, T. Shimosegawa, K. Kitamura, K. Takeda, Y. Takeyama, T. Mayumi,                   [61]   L. Huang, D.J. Sexton, K. Skogerson, M. Devlin, R. Smith, I. Sanyal, et al., Novel
      et al., Continuous regional arterial infusion versus intravenous administration of                  peptide inhibitors of angiotensin-converting enzyme 2, J. Biol. Chem. 278 (18)
      the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis:                 (2003) 15532–15540.
      a multicenter, randomized, open-label, phase 2 trial, J. Gastroenterol. 55 (3)               [62]   K.B. Pedersen, S. Sriramula, K.H. Chhabra, H. Xia, E. Lazartigues, Species-speciﬁc
      (2020) 342–352.                                                                                     inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implica-
 [35] M. Yamamoto, S. Matsuyama, X. Li, M. Takeda, Y. Kawaguchi, J.I. Inoue, et al.,                      tion for ACE2 activity assays, Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 (5)
      Identiﬁcation of nafamostat as a potent inhibitor of middle east respiratory syn-                   (2011) R1293–R1299.
      drome coronavirus S protein-mediated membrane fusion using the split-protein-                [63]   M. Ye, J. Wysocki, F.R. Gonzalez-Pacheco, M. Salem, K. Evora, L. Garcia-Halpin,
      based cell-cell fusion assay, Antimicrob. Agents Chemother. 60 (11) (2016)                          et al., Murine recombinant angiotensin-converting enzyme 2: eﬀect on angiotensin
      6532–6539.                                                                                          II-dependent hypertension and distinctive angiotensin-converting enzyme 2 in-
 [36] M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, et al., Remdesivir and chlor-                    hibitor characteristics on rodent and human angiotensin-converting enzyme 2,
      oquine eﬀectively inhibit the recently emerged novel coronavirus (2019-nCoV) in                     Hypertension 60 (3) (2012) 730–740.
      vitro, Cell Res. 30 (3) (2020) 269–271.                                                      [64]   J.L. Guy, R.M. Jackson, H.A. Jensen, N.M. Hooper, A.J. Turner, Identiﬁcation of
 [37] W. Li, M.J. Moore, N. Vasilieva, J. Sui, S.K. Wong, et al., Angiotensin-converting                  critical active-site residues in angiotensin-converting enzyme 2 (ACE2) by site-
      enzyme 2 is a functional receptor for the SARS coronoavirus, Nature 426 (6965)                      directed mautagenesis, FEBS J. 272 (14) (2005) 3512–3520.
      (2003) 450–454.                                                                              [65]   D.P. Han, A. Penn-Nicholson, M.W. Cho, Identiﬁcation of critical determinants on
 [38] X.Y. Ge, J.L. Li, X.L. Xang, A.A. Chumura, G. Zhu, J.H. Epstein, et al., Isolation and              ACE2 for SARS-CoV entry and development of a potent entry inhibitor, Virology
      characterization of a bat SARS-like coronavirus that uses the ACE2 receptor,                        350 (1) (2006) 15–25.
      Nature 503 (7477) (2013) 535–538.                                                            [66]   A. Mores, M. Matziari, F. Beau, P. Cuniasse, A. Yiotakis, V. Dive, Development of
 [39] W. Song, M. Gui, X. Wang, Y. Xiang, Cryo-EM structure of the SARS coronavirus                       potent and selective phosphinic peptide inhibitors of angiotensin-converting en-
      spike glycoprotein in complex with its host cell receptor ACE2, PLoS Pathol. 14 (8)                 zyme 2, J. Med, Chem. 51 (7) (2008) 2216–2226.
      (2018) e1007236.                                                                             [67]   A.J. Trask, L. Groban, B.M. Westwood, J. Varagic, D. Ganten, P.E. Gallagher, et al.,
 [40] A.J. Turner, S.R. Tipnis, J.L. Guy, G. Rice, N.M. Hooper, ACEH/ACE2 is a novel                      Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy
      mammalian metallocarboxypeptidase and a homologue of angiotensin-converting                         and ﬁbrosis in Ren-2 hypertensive rats, Am. J. Hypertens. 23 (6) (2010) 687–693.
      enzyme insensitive to ACE inhibitors, Can. J. Physiol. Pharmacol. 80 (4) (2002)              [68]   M.J. Huentelmann, J. Zubcevic, J.A. Hernandez Prada, X. Xiao, D.S. Dimitrov,
      346–353.                                                                                            M.K. Raizada, et al., Structure-based discovery of a novel angiotensin-converting
 [41] I. Ben-Zvi, S. Kivity, P. Langevitz, Y. Shoenfeld, Hydroxychloroquine: from malaria                 enzyme 2 inhibitor, Hypertension 44 (6) (2004) 903–906.
      to autoimmunity, Clin. Rev. Allergy Immunol. 42 (2) (2012) 145–153.                          [69]   S. Haga, N. Nagata, T. Okamura, N. Yamamoto, T. Sata, N. Yamamoto, et al., TACE
 [42] A. Savarino, L. Di Trani, I. Donatelli, R. Cauda, A. Cassone, New insights into the                 antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are
      antiviral eﬀects of chloroquine, Lancet Infect. Dis. 6 (2) (2006) 67–69.                            candidate antiviral compounds, Antiviral Res. 85 (3) (2010) 551–555.
 [43] Y. Yan, Z. Zou, Y. Sun, X. Li, K.F. Xu, Y. Wei, et al., Anti-malaria drug chloroquine        [70]   K.M. Mohler, P.R. Sleath, J.N. Fitzner, D.P. Ceretti, M. Anderson, S.S. Kerwar,
      is highly eﬀective in treating avian inﬂuenza A H5N1 virus infection in an animal                   et al., Protection against a lethal dose of endotoxin by an inhibitor of tumour
      model, Cell Res. 32 (2) (2013) 300–302.                                                             necrosis factor processing, Nature 370 (6486) (1994) 218–220.
 [44] M.J. Vincent, E. Bergeron, S. Benjannet, B.R. Erickson, P.E. Rollin, T.G. Ksiazek,           [71]   M. Takahashi, Y. Terada, I. Nakai, H. Nakanishi, E. Yoshimura, S. Mori, et al., Role
      et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread,                 of nicotianamide in the intracellular delivery of metals and plant reproductive
      Virol. J. 2 (August 22) (2005) 69.                                                                  development, Plant Cell 15 (6) (2003) 1263–1280.
 [45] M.A.A. Al-Bari, Targeting endosomal acidiﬁcation by chloroquine analogs as a                 [72]   S. Takahashi, T. Yoshiya, K. Yoshizawa-Kumagaye, T. Sugiyama, Nicotianamide is
      promising strategy for the treatment of emerging viral diseases, Pharmacol. Res.                    a novel angiotensin-converting enzyme 2 inhibitor in soybean, Biomed. Res. 36 (3)
      Perspect. 5 (1) (2017) e00293.                                                                      (2015) 219–224.
 [46] E. Keyaerts, L. Vijge, P. Maes, J. Neyts, M. Van Ranst, In vitro inhibition of severe        [73]   C. Naujokat, D.L. McKee, The "big ﬁve" phytochemicals targeting cancer stem
      acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res.                       cells: curcumin, EGCG, sulforaphane, resveratrol and genistein, Curr. Med. Chem.
      Commun. 323 (1) (2004) 264–268.                                                                     (February 27) (2020), https://doi.org/10.2174/0929867327666200228110738.
 [47] X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang, P. Nui, et al., In vitro antiviral activity       [74]   V. Monteil, H. Kwon, P. Prado, A. Hagelkrüys, R.A. Wimmer, M. Stahl, et al.,
      and projection of optimized dosing design of hydroxychloroquine for the treat-                      Inhibition of SARS-CoV2 infections in engineered human tissues using clinical-
      ment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin.                         grade soluble human ACE2, Cell (2020), https://doi.org/10.1016/j.cell.2020.04.
      Infect. Dis. (March 9) (2020), https://doi.org/10.1093/cid/ciaa237 pii: ciaa237..                   004.
 [48] J. Gao, Z. Tian, X. Yang, Breakthrough: Chloroquine phosphate has shown ap-                  [75]   T.K. Warren, R. Jordan, M.K. Lo, A.S. Ray, R.L. Mackman, V. Soloveva, et al.,
      parent eﬃcacy in treatment of COVID-19 associated pneumonia in clinical studies,                    Therapeutic eﬃcacy of the small molecule GS-5734 against Ebola virus in rhesus
      Biosci. Trends 14 (1) (2020) [53].                                                                  monkeys, Nature 531 (7594) (2016) 381–385.
 [49] R. Stahlmann, H. Lode, Medication for COVID-19 – an overview of approaches                   [76]   M.K. Lo, R. Jordan, A. Arvey, J. Sudhamsu, P. Shrivastava-Ranjan, A.L. Hotard,
      currently under study, Arztebl. 117 (13) (2020) 213–219 (2020) 72-73..                              et al., GS-5734 and its parent nucleoside analog inhibit ﬁlo-, pneumo-, and
 [50] P. Gautret, J.C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, et al.,                       paramyxoviruses, Sci. Rep. 7 (1) (2017) 43395.
      Hydroxychloroquine and azithromycin as a tratment of COVID-19: results of an                 [77]   T.P. Sheahan, A.C. Sims, R.L. Graham, V.D. Menachery, L.E. Gralinski, J.B. Case,


                                                                                               8


D.L. McKee, et al.                                                                                                                                 Pharmacological Research 157 (2020) 104859


        et al., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic                  [115] NCT04273763, ClinicalTrials.gov, (2020), Feb 18.
        coronaviruses, Sci. Transl. Med. 9 (396) (2017) eaal3653.                                     [116] NCT04286503, ClinicalTrials.gov, (2020), Feb 27.
 [78]   M.L. Agostini, E.L. Andres, A.C. Sims, R.L. Graham, T.P. Sheahan, X. Lu, et al.,              [117] Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, et al., In
        Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the                 vitro and in vivo activities of anti-inﬂuenza virus compound T-705, Antimicrob.
        viral polymerase and the proofreading exoribonuclease, mBio. 9 (2) (2018)                           Agents Chemother. 46 (4) (2002) 977–981.
        e00221–18.                                                                                    [118] Y. Furuta, T. Komeno, T. Nakamura, Favipiravir (T-705), A broad spectrum in-
 [79]   E.P. Tchesnokov, J.Y. Feng, D.P. Porter, M. Götte, Mechanisms of inhibition of                      hibitor of viral RNA polymerase, Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 93 (7)
        Ebola virus RNA-dependent RNA polymerase by remdesivir, Viruses 11 (4) (2019)                       (2017) 449–463.
        326.                                                                                          [119] Z. Jin, L.K. Smith, V.K. Rajwanshi, B. Kim, J. Deval, The ambiguous base-pairing
 [80]   C.J. Gordon, E.P. Tchesnokov, J.Y. Feng, D.P. Porter, M. Götte, The antiviral                       and high substrate eﬃciency of T-705 (favipiravir) ribofuranosyl 5’-triphosphate
        compound remdesivir potently inhibits RNA-dependent RNA polymerase from                             towards inﬂuenza A virus polymerase, PLoS One 8 (7) (2014) e68347.
        middle east respiratory syndrome coronavirus, J. Biol. Chem. (February 24)                    [120] L. Delang, R. Abdelnabi, J. Neyts, Favipiravir as a potential countermeasure
        (2020), https://doi.org/10.1074/jbc.AC120.013056.                                                   against neglected and emerging RNA viruses, Antiviral Res. 153 (2018) 85–94.
 [81]   E. de Wit, F. Feldmann, J. Cronin, R. Jordan, A. Okumura, T. Thomas, et al.,                  [121] Y. Furuta, K. Takahashi, K. Shiraki, K. Sakamoto, D.F. Smee, D.L. Barnard, et al., T-
        Prophylactic and therapeutic remdesivir (GS-5734) treatment in the 345 rhesus                       705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA
        macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. U.S.A. (February 13)                    viral infections, Antiviral Res. 82 (3) (2009) 95–102.
        (2020), https://doi.org/10.1073/pnas.1922083117.                                              [122] D. Sissoko, C. Laouenan, E. Folkesson, A.B. M´Lebing, A.H. Beavogui, S. Baize,
 [82]   S. Mulangu, L.E. Dodd, R.T. Davey, O. Thsihani Mbaya, M. Proschan, D. Mukadi,                       et al., Experimental treatment with favipiravir for Ebola virus disease (the JIKI
        et al., A randomized, controlled trial of Ebola virus disease therapeutics, N. Engl. J.             Trial): a historically controlled, single-arm proof-of-concept trial in Guinea, PLoS
        Med. 381 (24) (2019) 2293–2303.                                                                     Med. 13 (3) (2016) e1001967.
 [83]   J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, et al.,                    [123] NCT04310228, ClinicalTrials.gov, (2020), Mar 17.
        Compassionate use of remdesivir for patients with severe COVID-19, N. Engl. J.                [124] NCT04303299, ClinicalTrials.gov, (2020), Mar 11.
        Med. (April 10) (2020), https://doi.org/10.1056/NEJMoa2007016.                                [125] K. Anand, J. Ziebuhr, P. Wadhwani, J.R. Mesters, R. Hilgenfeld, Coronavirus main
 [84]   NCT04252664, ClinicalTrials.gov, (2020), Feb 5.                                                     protease (3CLpro) structure: basis for design of anti-SARS drugs, Science 300
 [85]   NCT04257656, ClinicalTrials.gov, (2020), Feb 6.                                                     (5626) (2003) 1763–1767.
 [86]   NCT04280705, ClinicalTrials.gov, (2020), Feb 21.                                              [126] L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, et al., Crystal
 [87]   NCT04292730, ClinicalTrials.gov, (2020), Mar 3.                                                     structure of SARS-CoV-2 main protease provides a basis for design of improved α-
 [88]   NCT04292899, ClinicalTrials.gov, (2020), Mar 3.                                                     ketoamide inhibitors, Science (March 20) (2020), https://doi.org/10.1126/
 [89]   NCT04302766, ClinicalTrials.gov, (2020), Mar 10.                                                    science.abb3405.
 [90]   NCT04314817, ClinicalTrials.gov, (2020), Mar 19.                                              [127] Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, et al., Structure of Mpro from
 [91]   NCT04315948, ClinicalTrials.gov, (2020), Mar 20.                                                    COVID-19 virus and discovery of its inhibitors, Nature (April 9) (2020), https://
 [92]   H.L. Sham, D.J. Kempf, A. Molla, K.C. Marsh, G.N. Kumar, C.M. Chen, et al., ABT-                    doi.org/10.1038/s41586-020-2223-y.
        378, a highly potent inhibitor of the human immunodeﬁciency virus protease,                   [128] H. Lim, D.S. Min, H. Park, H.P. Kim, Flavonoids interfere with NLRP3 inﬂamma-
        Antimicrob. Agents Chemother. 42 (12) (1998) 3218–3224.                                             some activation, Toxicol. Appl. Pharmacol. 355 (2018) 93–102.
 [93]   C.A. Benson, S.G. Deeks, S.C. Brun, R.M. Gulick, J.J. Eron, H.A. Kessler, et al.,             [129] I.Y. Chen, M. Moriyama, M.F. Chang, T. Ichinohe, Severe acute respiratory syn-
        Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and                drome coronavirus viroporin 3a activates the NLRP3 inﬂammasome, Front.
        2 nucleoside reverse-transcriptase inhibitors in human immunodeﬁciency virus                        Microbiol. 10 (50) (2019), https://doi.org/10.3389/fmicb.2019.00050.
        type 1-infected protease inhibitor-experienced patients, J. Infect. Dis. 185 (5)              [130] B.C. Zhang, Z. Li, W. Xu, C.H. Xiang, Y.F. Ma, Luteolin alleviates NLRP3 in-
        (2002) 599–607.                                                                                     ﬂammasome activation and directs macrophage polarization in lipopoly-
 [94]   A.H. Corbett, M.L. Lim, A.D. Kashuba, Kaletra (lopinavir/ritonavir), Ann.                           saccharide-stimulated RAW264.7 cells, Am. J. Transl. Res. 10 (1) (2018) 265–273.
        Pharmacother. 36 (7-8) (2002) 1193–1203.                                                      [131] H. Chen, H. Lin, S. Xie, B. Huang, Y. Qian, K. Chen, et al., Myricetin inhibits NLRP3
 [95]   C.M. Chu, V.C.C. Cheng, I.F.N. Hung, M.M.L. Wong, K.H. Chan, K.S. Chan, Role of                     inﬂammasome activation via reduction of ROS-dependent ubiquitination of ASC
        lopinavir/ritonavir in the treatment of SARS: initial virological and clinical ﬁnd-                 and promotion of ROS-independent NLRP3 ubiquitination, Toxicol. Appl.
        ings, Thorax 59 (3) (2004) 252–256.                                                                 Pharmacol. 365 (2019) 19–29.
 [96]   J.F. Chan, Y. Yao, M.L. Yeung, W. Deng, L. Bao, L. Jia, Treatment with lopinavir/             [132] K. Yamagata, K. Hashiguchi, H. Yamamoto, M. Tagami, Dietary apigenin reduces
        ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-                        induction of LOX-1 and NLRP3 expression, leukocyte adhesion, and acetylated
        human primate model of common marmoset, J. Infect. Dis. 212 (12) (2015)                             low-density lipoprotein uptake in human endothelial cells exposed to trimethy-
        1904–1913.                                                                                          lamine-N-oxide, J. Cardiovasc. Pharmacol. 74 (6) (2019) 558–565.
 [97]   Y.M. Arabi, A.Y. Asiri, A.M. Assiri, H.A. Aziz Jokhdar, A. Alothman, H.H. Balkhy,             [133] J.Y. Choe, S.K. Kim, Quercetin and ascorbic acid suppress fructose-induced NLRP3
        et al., Treatment of Middle East respiratory syndrome with a combination of lo-                     inﬂammasome activation by blocking intracellular shuttling of TXNIP in human
        pinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for                 macrophage cell lines, Inﬂammation 40 (3) (2017) 980–994.
        a recursive two-stage group sequential randomized controlled trial, Trials 21 (1)             [134] H. Lim, D.S. Min, H. Park, H.P. Kim, Flavonoids interfere with NLRP3 inﬂamma-
        (2020) 8.                                                                                           some activation, Toxicol. Appl. Pharmacol. 355 (2018) 93–102.
 [98]   B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, et al., A trial of lopinavir-               [135] S. Fu, L. Xu, S. Li, Y. Qiu, Y. Liu, Z. Wu, Baicalin suppresses NLRP3 inﬂammasome
        ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med. (March 18)                  and nuclear factor-kappa B (NF-κB) signaling during haemophilus parasuis in-
        (2020), https://doi.org/10.1056/NEJMoa2001282.                                                      fection, Vet. Res. 47 (1) (2016) 80.
 [99]   NCT04255017, ClinicalTrials.gov, (2020), Feb 5.                                               [136] Y. Sun, Y. Zhao, J. Yao, L. Zhao, Z. Wu, Y. Wang, Wogonoside protects against
[100]   NCT04261907, ClinicalTrials.gov, (2020), Feb 10.                                                    dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB
[101]   NCT04286503, ClinicalTrials.gov, (2020), Feb 27.                                                    and NLRP3 inﬂammasome activation, Biochem. Pharmacol. 94 (2) (2015)
[102]   NCT04295551, ClinicalTrials.gov, (2020), Mar 4.                                                     142–154.
[103]   NCT04276688, ClinicalTrials.gov, (2020), Feb 19.                                              [137] W. Dai, J. Bi, F. Li, S. Wang, X. Huang, X. Meng, Antiviral eﬃcacy of lavonoids
[104]   NCT04307693, ClinicalTrials.gov, (2020), Mar 13.                                                    against enterovirus 71 infection in vitro and in newborn mice, Viruses 11 (7)
[105]   J. Blaising, S.J. Polyak, E.I. Pécheur, Arbidol as a broad sprctrum antivital: un                   (2019) 625.
        update, Antiviral Res. 107 (2014) 84–94.                                                      [138] E. Moghaddam, B.T. Teoh, S.S. Sam, R. Lani, P. Hassandarvish, Z. Chik, et al.,
[106]   I.A. Leneva, R.J. Russell, Y.S. Boriskin, A.J. Hay, Characteristics of arbidol-re-                  Baicalin, a metabolite of baicalein with antiviral activity against dengue virus, Sci.
        sistant mutants of inﬂuenza virus: implications for the mechanism of anti-inﬂu-                     Rep. 4 (2014) 5452.
        enza action of arbidol, Antiviral Res. 81 (2) (2009) 132–140.                                 [139] T.Y. Ho, S.L. Wu, J.C. Chen, C.C. Li, C.Y. Hsiang, Emodin blocks the SARS cor-
[107]   Y.S. Boriskin, E.I. Pécheur, S.J. Polyak, Arbidol: a broad-spectrum antiviral that                  onavirus spike protein and angiotensin-converting enzyme 2 interaction, Antiviral
        inhibits acute and chronic HCV infection, Virol. J. 3 (2006) 56.                                    Res. 74 (2) (2007) 92–101.
[108]   J. Blaising, P.L. Lévy, S.J. Polyak, M. Stanifer, S. Boulant, E.I. Pécheur, Arbidol           [140] S.C. Lin, C.T. Ho, W.H. Chuo, S. Li, T.T. Wang, C.C. Lin, Eﬀective inhibition of
        inhibits viral entry by interfering with clathrin-dependent traﬃcking, Antiviral                    MERS-CoV infection by resveratrol, BMC Infect. Dis. 17 (1) (2017) 144.
        Res. 100 (1) (2013) 215–219.                                                                  [141] K. Kupferschmidt, J. Cohen, WHO launches global megatrial of the four most
[109]   E.I. Pécheur, V. Borisevich, P. Halfmann, J.D. Morrey, D.F. Smee, M. Prichard,                      promising coronavirus treatments, Science (March 2) (2020), https://www.
        et al., The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic                 sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-
        viruses, J. Virol. 90 (6) (2016) 3086–3092.                                                         promising-coronavirus-treatments.
[110]   C.E. Hulseberg, L. Fénéant, K.M. Szymanska de Wijs, N.P. Kessler, E.A. Nelson,                [142] O. Mitja, B. Clotet, Use of antiviral drugs to reduce COVID-19 transmission, Lancet
        C.J. Shoemaker, et al., Arbidol and other low-molecular-weight drugs that inhibit                   Glob. Health (March 19) (2020), https://doi.org/10.1016/S2214-109X(20)
        Lassa and Ebola viruses, J. Virol. 93 (8) (2019) e02185–18.                                         30114-5.
[111]   Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical features of 69 cases with                 [143] R. Wölfel, V.C. Corman, W. Guggemos, M. Seilmaier, S. Zange, M.A. Müller, et al.,
        coronavirus disease 2019 in Wuhan, China, Clin. Infect. Dis. (March 16) (2020),                     Virological assessment of hospitalized patients with COVID-19, Nature (April 1)
        https://doi.org/10.1093/cid/ciaa272.                                                                (2020), https://doi.org/10.1038/s41586-020-2196-x.
[112]   L. Deng, C. Li, Q. Zeng, X. Liu, X. Li, H. Zhang, et al., Arbidol combined with LPV/r         [144] T.P. Sheahan, A.C. Sims, S. Zhou, R.L. Graham, A.J. Pruijssers, M.L. Agostini, et al.,
        versus LPV/r alone against corona virus disease 2019: a retrospective cohort                        An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human
        study, J. Infect. (March 11) (2020), https://doi.org/10.1016/j.jinf.2020.03.002.                    airway epithelial cell cultures and multiple coronaviruses in mice, Sci. Transl.
[113]   NCT04255017, ClinicalTrials.gov, (2020), Feb 5.                                                     Med. (April 4) (2020), https://doi.org/10.1126/scitranslmed.abb5883.
[114]   NCT04260594, ClinicalTrials.gov, (2020), Feb 7.


                                                                                                  9
